Industry
Biotechnology
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:03 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 1:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 2:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:20 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 12:00 pm
Portfolio Pulse from Avi Kapoor
May 22, 2024 | 11:35 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 4:40 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 10:46 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
April 11, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.